Related Experiment Video
Updated: Jun 22, 2026
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
[Purification of fusion protein HSA/IL1ra and its bioactivity]
1Institute of Pharmacology, Toxicology and Biological Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Objective:
To purify the recombinant human serum albumin fusion protein with interleukin 1 (HAS/IL1ra) and to detect the bioactivity of the fusion protein.
Methods:
The recombinant HAS/IL1ra protein was purified by affinity chromatography and ion exchange chromatography, the bioactivity of the fusion protein was detected by IL1-induced A375 S2 cell killing.
Result:
The purity of the fusion protein was at least 98 % as assessed by HPLC and the protective effect from the IL1-induced A375 S2 cell killing was similar to natural IL1ra.
Conclusion:
The purified recombinant HAS/IL1ra protein in this study has a satisfactory bioactivity.
